Marks Group Wealth Management Inc Has $1.32 Million Stake in GSK plc (NYSE:GSK)

Marks Group Wealth Management Inc cut its stake in shares of GSK plc (NYSE:GSK) by 5.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 38,900 shares of the pharmaceutical company’s stock after selling 2,044 shares during the quarter. Marks Group Wealth Management Inc’s holdings in GSK were worth $1,316,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. FMR LLC lifted its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC lifted its position in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Primecap Management Co. CA lifted its position in shares of GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after purchasing an additional 342,365 shares during the period. Provident Trust Co. boosted its stake in shares of GSK by 1.7% in the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after purchasing an additional 66,765 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its stake in GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after buying an additional 833,080 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Morgan Stanley started coverage on GSK in a report on Wednesday. They issued an “equal weight” rating for the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.2 %

Shares of NYSE:GSK opened at $36.15 on Thursday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The business’s 50 day simple moving average is $34.31 and its two-hundred day simple moving average is $37.51. The firm has a market cap of $74.92 billion, a P/E ratio of 22.74, a PEG ratio of 1.42 and a beta of 0.64.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, research analysts forecast that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.35%. GSK’s payout ratio is presently 93.08%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.